387 related articles for article (PubMed ID: 26633468)
1. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Turnbull S; West EJ; Scott KJ; Appleton E; Melcher A; Ralph C
Viruses; 2015 Dec; 7(12):6291-312. PubMed ID: 26633468
[TBL] [Abstract][Full Text] [Related]
2. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
3. Reovirus: viral therapy for cancer 'as nature intended'.
Comins C; Heinemann L; Harrington K; Melcher A; De Bono J; Pandha H
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):548-54. PubMed ID: 18583112
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy.
Cervantes-García D; Ortiz-López R; Mayek-Pérez N; Rojas-Martínez A
Ann Hepatol; 2008; 7(1):34-45. PubMed ID: 18376364
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical experience with oncolytic viruses.
Donnelly OG; Errington-Mais F; Prestwich R; Harrington K; Pandha H; Vile R; Melcher AA
Curr Pharm Biotechnol; 2012 Jul; 13(9):1834-41. PubMed ID: 21740364
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viruses move forward in clinical trials.
Rowan K
J Natl Cancer Inst; 2010 May; 102(9):590-5. PubMed ID: 20421567
[No Abstract] [Full Text] [Related]
8. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
Kaur B; Chiocca EA; Cripe TP
Curr Pharm Biotechnol; 2012 Jul; 13(9):1842-51. PubMed ID: 21740359
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy progress and prospects cancer: oncolytic viruses.
Liu TC; Kirn D
Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
11. Current strategies of virotherapy in clinical trials for cancer treatment.
Lin W; Zhao Y; Zhong L
J Med Virol; 2021 Aug; 93(8):4668-4692. PubMed ID: 33738818
[TBL] [Abstract][Full Text] [Related]
12. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
Park GT; Choi KC
Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
[TBL] [Abstract][Full Text] [Related]
13. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
Liu TC; Kirn D
Cancer Res; 2007 Jan; 67(2):429-32. PubMed ID: 17234747
[TBL] [Abstract][Full Text] [Related]
14. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
15. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
16. Systemic virotherapy for multiple myeloma.
Oliva S; Gambella M; Boccadoro M; Bringhen S
Expert Opin Biol Ther; 2017 Nov; 17(11):1375-1387. PubMed ID: 28796556
[TBL] [Abstract][Full Text] [Related]
17. Clinical development directions in oncolytic viral therapy.
Eager RM; Nemunaitis J
Cancer Gene Ther; 2011 May; 18(5):305-17. PubMed ID: 21436867
[TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
19. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
20. Viruses as nanomedicine for cancer.
Badrinath N; Heo J; Yoo SY
Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
